UTILISATION DE VIRUS DE LA VACCINE ANKARA MODIFIE (MVA) NON REPLICATIF INACTIVE EN TANT QUE MONO-IMMUNOTHERAPIE OU EN ASSOCIATION AVEC DES AGENTS DE BLOCAGE DE POINT DE CONTROLE POUR DES TUMEURS SOLIDES

• 收藏
• 分享

专利权人:

MEMORIAL SLOAN-KETTERING CANCER CENTER

发明人:

DENG, LIANG,SHUMAN, STEWART,WOLCHOK, JEDD D.,MERGHOUB, TAHA,DAI, PEIHONG,WANG, WEIYI

申请号：

CA2977660

公开号：

CA2977660A1

申请日:

2016.02.25

申请国别(地区):

CA

年份:

2016

代理人:

摘要：

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/